Autoimmune Diseases; Hepatitis
Public Health Interests
I am evaluating the role of an inflammatory protein called MIF in autoimmune hepatitis and its ability to be a predictor of disease severity, response to therapy, and a predictor of disease relapse.
I am evaluating alternative therapies for the treatment of Primary Sclerosing Cholangitis.
Extensive Research Description
I am investigating the role of macrophage migration inhibitory factor (MIF) in autoimmune hepatitis. Active studies involve serial measurement of serum MIF and its soluble receptor (CD74) in the blood of patients with autoimmune hepatitis, to evaluate if these proteins can serve as biomarkers of disease activity.
I am evaluating cellular mechanisms of the release of the CD74 protein and its neutralizing activity on the cytokine MIF.
I am investigating the role of MIF in the pathophysiology of autoimmune hepatitis in animal models of disease.
I am evaluating alternative therapies for Primary Sclerosing Cholangitis (PSC) including all-trans retinoic acid and fenofibrate.
A study of the role of macrophage migration inhibitory factor (MIF) in autoimmune hepatitis, through clinical and translational investigations.
A study of the role of all-trans retinoic acid (ATRA) for the treatment of Primary Sclerosing Cholangitis (PSC), in collaboration with Dr. James Boyer.